The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy

American Heart Journal

Volumn 137, Issue 5, 1999, Pages

  Califf, Robert M ^a   Stump, David ^b   Topol, Eric J ^b   Mark, Daniel B ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STREPTOKINASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DOSE RESPONSE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MORTALITY; PRIORITY JOURNAL; SURVIVAL TIME; ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; NORTH AMERICA; RETROSPECTIVE STUDY;

CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DECISION MAKING; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; NORTH AMERICA; RETROSPECTIVE STUDIES; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0033129352     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70438-2     Document Type: Conference Paper

References (16)

1. 1. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group, ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1993;339:753-70.
2. 2. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplose and streptokinase with or without heparin. Lancet 1990;336;71-5.
3. 3. The GUSTO Investigators. An international randomized trial comparing four thrombolytic regimens consisting of tissue plasminogen activator, streptokinase, or both for acute myocardial infarction. N Engl J Med 1993;329:673-82.
4. 4. Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993;87:1792-805.
5. 5. Califf RM, Topol EJ, Gersh BJ. From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. J Am Coll Cardiol 1989;14:1382-8.
6. 6. Gruppo Italiano per lo Studio della Streptochinaisi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
7. 7. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. ISIS-2. Lancet 1988;2:349-60.
8. 8. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988;2:545-9.
9. 9. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR, for the ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988;2:525-30.
10. 10. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase 1 findings. N Engl J Med 1985;312:932.
11. 11. Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989;14: 1566-9.
12. 12. Neuhaus KL, Von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: result of the rt-PA-APSAC patency study [TAPS]. J Am Coll Cardiol 1992;19:885-91.
13. 13. Carney RJ, Murphy GA, Brandt TR, et al. Randomized angiographic trial of recombinant tissue type plasminogen activator (alteplase) in myocardial infarction. J Am Coll Cardiol 1992;2017-23.
14. 14. Wall TC, Califf RM, George BS, et al, for the TAMI-7 Study Group. Accelerated plasminogen activator dose regimens for coronary thrombolysis. J Am Coll Cardiol 1992;19:482-9.
15. 15. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332:1418-24.
16. 16. Califf RM, White HD, Van der Werf F, et al, for the GUSTO-I Investigators. One-year results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO-I) trial. Circulation 1996;94:1233-8.